Skip to main content

Vallon Pharmaceuticals stock plunges 70% after ADHD drug candidate misses primary endpoint

The company suffered a setback with its proprietary abuse-deterrent formulation of dextroamphetamine to treat ADHD.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.